#Opdivo

FDA Approves Opdivo for Small Cell Lung Cancer

Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.

Opdivo and Keytruda are potential alternatives to current first-line therapies.

Opdivo plus Cabometyx reduced the risk of death by 40%.

Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.

Stivarga also improved survival in those with recurrent HCC after a liver transplant.

Margaret has never stopped living and enjoying her life despite her disease and the side effects of her medication.

Checkpoint inhibitor extended survival by about three months compared with chemotherapy.

The combination led to improved overall survival compared with chemotherapy.

Cancer-fighting T cells led to complete or partial tumor remission in at least 25% of lung cancer patients.

In a small, early-stage study, the PD-1 checkpoint inhibitor was effective against only some cases of pediatric lymphoma.

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."

Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.

A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.